In this issue:
Comparing brentuximab vedotin and nivolumab
Chemotherapy-free combination
Response-adapted radiation therapy
Long-term survival after CAR T-cell therapy
Determining a phase 2 dosage of ziftomenib
Redefining prognostic classification for T-ALL
TEFA-LEN pre and post CAR T-cell therapy
Efficacy of nilotinib and dasatinib
Bridging therapy prior to CAR T-cell therapy
GELFc and treatment decision-making
Please login below to download this issue (PDF)